Flow Cytometry 2012: A Focus on Sales Growth

Report Overview

Table of Contents

1850

Select License Type

£1,850.00	Electronic License Electronic License An electronic version (mostly PDF, but can be Excel or PPT), which is either available for immediate download or will be sent via email by the Publisher of the report. The licencing for an electronic version is for use by the purchaser ONLY.
£2,775.00	Site License Site License An electronic version (mostly PDF, but can be Excel or PPT). Where the report(s) is intended for use by more than one individual, across for example, a site, an office, or a division or country.
£3,500.00	Corporate License Corporate License An electronic version (mostly PDF, but can be Excel or PPT). Where the report(s) is/are intended for use by an organisation in its entirety. For example, if reports are put on an Intranet or if they are distributed or used by more than one office, division, or country operation, then a Corporate Licence is required.

£1,850.00	Add to Wishlist
Change Currency	GBP EURO USD
	Order By Fax

Market	Healthcare and Medical
Report Type	Market Research
Country	Global
Published	15 September 2012
Number of Pages	167
Report Delivery	Email
Delivery Lead Time	1-3 hours, 24 hour max
Publisher	Biopharm Reports
File Format	PDF

Flow cytometry market to hit value of $4 billion by 2015

From its development in the 1960s, flow cytometry (FC) has evolved into a technique that is now used routinely in the clinic, as well as in the research setting. The flow cytometry market is expected to grow to over $4 billion by 2015, however markets are also changing as new applications are developed and new instruments are launched. Today, more than ever, developers and vendors in this field are targeting their resources in those areas that best support their own sales and growth strategies.

Report Scope

This report, based on an analysis of prevailing and emerging market conditions in flow cytometry, has been produced to assist marketing and sales activities in this field, and the identification of new opportunities. It is the outcome of an extensive global study involving more than 260 experienced flow cytometry users. It's findings provide a "focus on sales growth" to developers and vendors in the flow cytometry field, and the changes that are driving new developments in this field.

As part of this report, market areas outlined below have been analysed to provide information relevant to marketing and sales, new market opportunities, qualified sales leads, customer needs and future plans, competitive position, new and emerging applications, growing and declining areas and threats.

Market Areas

- General methods: Current use of more than 25 FC general applications by end-users and the anticipated use of these over the next three years, each ranked according to their competitive position.

- Clinical methods: Current use of more than 15 clinical applications by end-users and the anticipated use of these over the next three years, each ranked according to their competitive position.

- Main applications: End-users' two main applications of FC, each ranked according to their competitive position.

- New applications: New FC applications used by end-users in the last three years, each ranked according to their competitive position.

- Emerging applications: Emerging applications of FC, indicated by end-users.

- Main flow cytometers: End-users' main flow cytometer, each ranked according to their competitive position.

- Strengths: End-users' disclosures of the strengths of their main flow cytometer, each ranked according to their competitive position.

- Weaknesses: End-users' disclosures of the weaknesses of their main flow cytometer, each ranked according to their competitive position.

- Routine use: The use of FC by end-users for routine (developed and validated) FC tests, the development or validation of FC tests and for qualitative discovery

- Suppliers: End-users' purchases/use of FC systems from more than 25 companies and their anticipated use of these systems over the next three years, each ranked according to their competitive position

- General and clinical: FC use by research scientists/research managers and clinicians/physicians

- Current budgets: End-users' annual financial budgets for FC studies.

- Budget breakdown: The breakdown of end-users' FC financial budgets in nine key areas, relating to their current expenditure on FC products and activities.

- Future budgets: End-users' anticipated financial budget changes (percentage increases or decrease, a measure of the financial growth of this field) over the next three years, relating to their FC activities.

- Consumables: End-users' top consumables, associated with their FC activities.

- Quality control guidelines: End-users' adherence to quality control guidelines or procedures, relating to the conduct of FC studies.

- Cost per sample: End-users' disclosures on the costs per sample analysed, using FC.

- Challenges: End-users' disclosures on the parameters or measurements that present the greatest technical challenges to FC analysis, together with the associated sample types (matrices), associated FC methods and underlying reasons.

- Innovation: End-users' disclosures relating to 11 key areas of required innovation in the FC field, each ranked (on a scale of 1 to 10) according to their importance.

- Biomarkers: End-users' application of FC methods for the study of disease biomarkers, namely molecular types and their clinical utilities.

- Organisations: End-users. organisations include clinics or hospitals, government bodies, large international companies, research institutes, small and medium sized companies, universities and veterinary centres.

- Fields: End-users professional fields include biotechnology, chemicals, clinical or hospital, defence, energy, environmental, food and drink, forensics, geology, government, healthcare, natural products, pharmaceuticals, research institutes, security and universities.

- Therapeutic areas: End-users' FC activities in terms of their general therapeutic area (20 different areas covered), including the main diseases to which their work in this field relates.

- Software: End-users' disclosures on their preferred analysis (off-line) software, associated with FC studies.

- Purpose: End-users' underlying reasons for using FC analysis across 17 major fields (biotechnology, chemicals, clinical or hospital, defence, diagnostics (medical), energy, environmental, food and drink, forensics, geology, government, healthcare, natural products, pharmaceuticals, research institutes, security, university), each ranked according to their relative importance.

- Study samples: Study sample types analysed by end-users using FC methods, each ranked according to their relative importance.

- Sample preparation: The use of sample preparation methods by end-users for FC studies, each ranked according to their importance.

Speak to an Advisor

Call us on
+44 (0) 203 086 8600

Select License Type

£1,850.00	Electronic License Electronic License An electronic version (mostly PDF, but can be Excel or PPT), which is either available for immediate download or will be sent via email by the Publisher of the report. The licencing for an electronic version is for use by the purchaser ONLY.
£2,775.00	Site License Site License An electronic version (mostly PDF, but can be Excel or PPT). Where the report(s) is intended for use by more than one individual, across for example, a site, an office, or a division or country.
£3,500.00	Corporate License Corporate License An electronic version (mostly PDF, but can be Excel or PPT). Where the report(s) is/are intended for use by an organisation in its entirety. For example, if reports are put on an Intranet or if they are distributed or used by more than one office, division, or country operation, then a Corporate Licence is required.

£1,850.00	Add to Wishlist
Change Currency	GBP EURO USD

1 Introduction

2 Study Participants

Investigated: Participants' countries, regions, organisation types, departments and professional fields. Figures and/or tables are also presented.

2.1 This chapter
2.2 Countries
2.3 Regions
2.4 Organisation types
2.5 Departments
2.6 Fields
2.7 Discussion

Fields:

- Biotechnology
- Chemicals
- Clinical or Hospital
- Defense
- Diagnostics (Medical)
- Energy
- Environmental
- Food and Drink
- Forensics
- Geology
- Government
- Healthcare
- Natural Products
- Pharmaceuticals
- Research Institute
- Security
- University
- Other

Organisation Types

- University
- Research Institute
- Small or Medium Sized Company
- Large International Company
- Clinic or Hospital
- Government Organisation
- Veterinary Organisation
- Other

3 Purpose of Flow Cytometry

Investigated: Participants' purpose or reasons for using flow cytometry in their specified fields (see Fields, Chapter 2). The purposes or reasons for using flow cytometry, which may be unique to particular fields, were taken into account. Example: The purpose or reasons for using flow cytometry in the "Clinical or Hospital" field were clinical research, routine diagnostics, routine screening, clinical trials, treatment monitoring, diagnostics research, disease research, drug R&D, drug targets, pathology, toxicology and other. Figures and/or tables are also presented.

3.1 This chapter
3.2 Purpose
3.3 Discussion

4 Main Activities

Investigated: The professional roles of study participants, namely as researchers or research managers, clinicians or physicians. Figures and/or tables are also presented.

4.1 This chapter
4.2 Researchers or Research Managers
4.3 Clinicians or Physicians
4.4 Discussion

5 Flow Cytometric Tests

Investigated: Participants' use of flow cytometry in one of three areas, namely i) the running of routine cytometric tests ii) the developing of new cytometric tests or iii) qualitative (cytometric) discovery. Figures and/or tables are also presented.

5.1 This chapter
5.2 Flow cytometric tests
5.3 Discussion

6 Therapeutic Area

Investigated: The therapeutic area(s) in which study participants work, relating to their use of flow cytometry. Figures and/or tables are also presented.

6.1 This chapter
6.2 Therapeutic Areas
6.3 Discussion

Therapeutic Areas

- Arthritis
- Autoimmune Diseases
- Bone Metabolism
- Cancer
- Cardiovascular
- Central Nervous System
- Dentistry
- Dermatology
- Endocrine
- Gastrointestinal
- Genito-urinary System
- Haematology
- Infections
- Inflammation
- Metabolic Disorders
- Musculoskeletal Disorders
- Nutrition
- Obstetrics and Gynaecology
- Ophthalmology
- Pain
- Psychiatry
- Respiratory
- Skin
- Other

7 Main Diseases

Investigated: The main disease areas in which study participants work, relating to their use of flow cytometry. Figures and/or tables are also presented.

7.1 This chapter
7.2 Disease areas
7.3 Discussion

8 Samples

Investigated: The sample types analysed by study participants, using flow cytometry. Figures and/or tables are also presented.

8.1 This chapter
8.2 Samples
8.3 Discussion

Sample Types

- Animal tissues
- Cerebrospinal fluid
- Bone Marrow
- Human tissues
- Microbiological materials
- Pathology samples
- Plant materials
- Lymph
- Saliva
- Urine
- Whole blood
- Other

9 General Applications

Investigated: Participants current and anticipated future use (2012 - 2015) of flow cytometry, in respect of 26 specified general applications, or others. Figures and/or tables are also presented.

9.1 This chapter
9.2 Current general applications
9.3 Anticipated future general applications
9.4 Discussion

General Application Areas

- ADME Studies
- Toxicity studies
- Apoptosis
- Bacteria analysis
- Bacterial membrane potential
- Bead-based immunoassays
- Cell adherence
- Cell cycle
- Cell signalling
- Cell sorting
- Cellular kinetics
- DNA and RNA content
- Protein expression
- FRET
- Immunophenotyping
- Intracellular calcium flux
- Membrane asymmetry
- Mitochondrial membrane potential
- Multicolour Flow Cytometry
- Necrosis
- Organelle function
- Protein expression and localization
- Rare event analysis
- Stem cell research
- T Cell immunology
- Transgenic products (e.g. GFP)
- Other

10 Clinical Applications

Investigated: Participants current and anticipated future use (2012 - 2015) of flow cytometry, in respect of 19 specified clinical applications, or others. Figures and/or tables are also presented.

10.1 This chapter
10.2 Current clinical applications
10.3 Anticipated future clinical applications
10.4 Discussion

Clinical Applications

- Cell counting
- Cell function
- Cell pigments
- Cell Proliferation
- Cell surface antigens (e.g. CD markers)
- Cell viability
- Diagnosis of haematologic malignancies
- DNA ploidy
- Enzymatic activity
- Infectious diseases
- Intracellular antigens
- Minimal residual disease
- Monitoring AIDS patients
- Monitoring chemotherapy
- Multidrug Resistance (MDR)
- Organ or stem-cell transplantation
- Platelet function analysis
- Transfusion medicine
- Volume and morphology of cells
- Other

11 Main Applications

Investigated: Participants main flow cytometry applications. Figures and/or tables are also presented.

11.1 This chapter
11.2 Main applications
11.3 Discussion

12 New Applications

Investigated: New flow cytometry applications that study participants anticipate they will be using in the next three years. Figures and/or tables are also presented.

12.1 This chapter
12.2 New applications
12.3 Discussion

13 Emerging Applications

Investigated: Emerging flow cytometry applications that study participants believe offer promise in their field. Figures and/or tables are also presented.

13.1 This chapter
13.2 Emerging applications
13.3 Discussion

14 Suppliers

Investigated: Participants current and an anticipated future (2012 - 2015) flow cytometry suppliers or vendors, in respect of 20 specified companies, or others. Figures and/or tables are also presented.

14.1 This chapter
14.2 Current suppliers
14.3 Future suppliers
14.4 Discussion

Suppliers

- Amnis (Millipore)
- Apogee Flow
- Applied Bioscience
- BD
- Beckman Coulter
- BioCytex
- Bio-Rad
- CytonomeST
- DVS Sciences
- iCyt (Sony)
- IntelliCyt
- Life Technologies
- Luminex
- Miltenyi
- Partec
- PointCare
- Stratedigm
- Sysmex
- TTP LabTech
- Union Biometrica
- Other

15 Main Flow Cytometer, Strengths and Weaknesses

Investigated: Participants main flow cytometer, in terms of their most frequently used system, together with their strengths and weaknesses. Figures and/or tables are also presented.

15.1 This chapter
15.2 Main flow cytometer
15.3 Discussion

16 Reagents and Assays

Investigated: Participants two main suppliers of reagents and assays for use in flow cytometry. Figures and/or tables are also presented.

16.1 This Chapter
16.2 Reagents and assays
16.3 Discussion

17 Sample Preparation

Investigated: Sample preparation methods used by participants, for flow cytometry studies. Figures and/or tables are also presented.

10.1 This Chapter
10.2 Sample Preparation
10.3 Discussion

18 Software

Investigated: Participants use of data analysis (offline) software, for flow cytometry studies. Figures and/or tables are also presented.

18.1 This Chapter
18.2 Software
18.3 Discussion

19 Challenges

Investigated: The measurements or parameters that present the greatest technical challenge to study participants, relating to their use of flow cytometry. The parameter, sample type (matrix) and cytometer used were indicated, together with the main underlying reasons. Figures and/or tables are also presented.

19.1 This chapter
19.2 Parameters
19.3 Sample type (matrix)
19.4 Flow cytometer
19.5 Reasons
19.6 Discussion

20 Innovation

Investigated: Participants views on areas of required innovation (ranked on a scale of 1 to 10, where 1 is the least important and 10 is the most important), in respect of 10 specified areas, or others. Figures and/or tables are also presented.

20.1 This chapter
20.2 Innovation
20.3 Discussion

Innovation Areas

- Automation
- Detectors
- Fluidics
- Lasers/Light Sources
- Offline (Analysis) software
- Online Data handling
- Qualitative selectivity
- Quantitative sensitivity
- Reagents
- Sample preparation
- Other

21 Disease Biomarkers

Investigated: Participants two main biomarkers investigated or measured using flow cytometry and their applications in terms of nine clinical utilities. Figures and/or tables are also presented.

21.1 This chapter
21.2 Biomarkers
21.3 Clinical utility
21.4 Discussion

Clinical Utilities

- Disease prognosis
- Disease susceptibility or risk
- Disease stage or severity
- Drug discovery
- Early detection of disease
- Clinical trial endpoint
- Guiding treatment
- Response to therapy
- Safety or toxicity factors
- Other

22 Flow Cytometry Expenditure and Budgets

Investigated: Financial expenditure and budgets relating to the current and future use of flow cytometry, including end-users' current annual budgets across specified ranges (see Current Annual financial budgets), the average flow cytometry analysis costs/sample across specified ranges (see Flow Cytometry Costs per Sample), budget breakdown across nine specified areas (see Budget Breakdown Areas) and overall annual financial budget for flow cytometry (either increasing or decreasing in % terms), over the next three years (see Future Budget Changes). Figures and/or tables are also presented.

22.1 This chapter
22.2 Annual budgets
22.3 Costs per sample
22.4 Budget breakdown
22.5 Future budget
22.6 Discussion

Current Annual Financial Budgets

- <$1 k
- $1 - $2.5k
- $2.5 - $5k
- $5 - $10k
- $10 - $25k
- $25 - $50k
- $50 - $100k
- $100 - $250k
- $250 - $500k
- $500k - $1 million
- $1 million - $2.5 million
- $2.5 million - $5 million
- >$5 m

Flow Cytometry Costs/Sample

- <$1
- $1 - $2
- $2 - $3
- $3 - $4
- $4 - $5
- $5 - $7
- $7 - $10
- $10 - $15
- $15 - $25
- $25 - $40
- $40 - $60
- $60 - $100
- $100 - $150
- $150 - $200
- $200 - $250
- >$250

Budget breakdown Areas

- Reagents and consumables
- System control (data handling) software
- Data analysis (offline) software
- Flow cytometer instruments
- Sample preparation and related instrumentation
- Ancillary systems/instrumentation
- General overheads
- Instrument servicing/repair
- Staff salaries
- Other

Future budget changes

Decreasing
- >-50%
- -50%
- -40%
- -30%
- -20%
- -10%
- -5%
- 0
- +5%
- +10%
- +20%
- +30%
- +40%
- +50%
- >+50%
Increasing

23 Consumables

Investigated: Participants two main consumables in terms of costs, that are directly associated with their use of flow cytometry. Figures and/or tables are also presented.

23.1 This Chapter
23.2 Consumables
23.3 Discussion

24 Quality Control

Investigated: Quality control systems or procedures adhered to in the use of flow cytometry. Figures and/or tables are also presented.

24.1 This chapter
24.2 Quality control
24.3 Discussion

List of Figures and Tables

Figure 2.1 Countries of individuals who participated in FC 2012
Figure 2.2 Global regions of individuals who participated in FC 2012.
Figure 2.3 Organisation types of individuals who participated in FC 2012
Figure 2.4 Fields of individuals who participated in FC 2012
Table 2.1 Countries of individuals who participated in FC 2012
Table 2.2 Global regions of individuals who participated in FC 2012
Table 2.3 Organisation types of individuals who participated in FC 2012

Figure 3.1 Top ten reasons for using FC in the biotechnology industry, indicated by individuals who participated in FC 2012
Figure 3.2 Top ten reasons for using FC in clinics or hospitals, indicated by individuals who participated in FC 2012
Figure 3.3 Top ten reasons for using FC in the energy industry, indicated by individuals who participated in FC 2012
Figure 3.4 Top ten reasons for using FC in diagnostics (medical), indicated by individuals who participated in FC 2012
Figure 3.5 Top ten reasons for using FC in the environmental industry, indicated by individuals who participated in FC 2012
Figure 3.6 Top ten reasons for using FC in the food and drink industry, indicated by individuals who participated in FC 2012
Figure 3.7 Top ten reasons for using FC in the Government organisations, indicated by individuals who participated in FC 2012
Figure 3.8 Top ten reasons for using FC in the healthcare industry, indicated by individuals who participated in FC 2012
Figure 3.9 Top ten reasons for using FC in the natural products industry, indicated by individuals who participated in FC 2012
Figure 3.10 Top ten reasons for using FC in the pharmaceutical industry, indicated by individuals who participated in FC 2012
Figure 3.11 Top ten reasons for using FC in research institutes, indicated by individuals who participated in FC 2012
Figure 3.12 Top ten reasons for using FC in universities, indicated by individuals who participated in FC 2012

Figure 4.1 Main activities of individuals using flow cytometry, indicated by individuals who participated in FC 2012

Figure 5.1 General flow cytometry tests carried out by individuals using flow cytometry, indicated by individuals who participated in FC 2012

Figure 6.1 Top ten therapeutic areas relating to the use of flow cytometry, indicated by individuals who participated in FC 2012
Table 6.1 Therapeutic areas relating to the use of flow cytometry, indicated by individuals who participated in FC 2012

Figure 7.1 Top ten main diseases relating to the use of flow cytometry, indicated by individuals who participated in FC 2012
Table 7.1 Main diseases relating to the use of flow cytometry, indicated by individuals who participated in FC 2012

Figure 8.1 Top ten sample types relating to the use of flow cytometry, indicated by individuals who participated in FC 2012
Table 8.1 Sample types relating to the use of flow cytometry, indicated by individuals who participated in FC 2012

Figure 9.1 Top ten general applications of flow cytometry, indicated by individuals who participated in FC 2012
Table 9.1 General applications of flow cytometry, indicated by individuals who participated in FC 2012
Figure 9.2 Top ten future (2012 - 2015) general applications of flow cytometry, indicated by individuals who participated in FC 2012
Table 9.2 Future (2012 - 2015) general applications of flow cytometry, indicated by individuals who participated in FC 2012

Figure 10.1 Top ten clinical applications of flow cytometry, indicated by individuals who participated in FC 2012
Table 10.1 Clinical applications of flow cytometry, indicated by individuals who participated in FC 2012
Figure 10.2 Top ten future (2012 - 2015) clinical applications of flow cytometry, indicated by individuals who participated in FC 2012
Table 10.2 Future (2012 - 2015) clinical applications of flow cytometry, indicated by individuals who participated in FC 2012

Figure 11.1 Top ten main applications in flow cytometry, indicated by individuals who participated in FC 2012
Table 11.1 Main applications in flow cytometry, indicated by individuals who participated in FC 2012

Figure 12.1 Top ten new applications in flow cytometry, indicated by individuals who participated in FC 2012
Table 12.1 New applications in flow cytometry, indicated by individuals who participated in FC 2012

Figure 13.1 Top ten emerging applications in flow cytometry, indicated by individuals who participated in FC 2012
Table 13.1 Emerging applications in flow cytometry, indicated by individuals who participated in FC 2012

Figure 14.1 Top ten suppliers of flow cytometry systems, indicated by individuals who participated in FC 2012
Table 14.1 Suppliers of flow cytometry systems, indicated by individuals who participated in FC 2012
Figure 14.1 Top ten future (2012 - 2015) suppliers of flow cytometry systems, indicated by individuals who participated in FC 2012
Table 14.1 Future (2012 - 2015) suppliers of flow cytometry systems, indicated by individuals who participated in FC 2012

Figure 15.1 Top ten main flow cytometers, indicated by individuals who participated in FC 2012
Table 15.1 Main flow cytometers, indicated by individuals who participated in FC 2012
Figure 15.2 Top ten strengths of main flow cytometers, indicated by individuals who participated in FC 2012
Table 15.2 Strengths of main flow cytometers, indicated by individuals who participated in FC 2012
Figure 15.3 Top ten weaknesses of main flow cytometers, indicated by individuals who participated in FC 2012
Table 15.3 Weaknesses of main flow cytometers, indicated by individuals who participated in FC 2012

Figure 16.1 Top ten reagents and assays used in flow cytometry, indicated by individuals who participated in FC 2012
Table 16.1 Reagents and assays used in flow cytometry, indicated by individuals who participated in FC 2012

Figure 17.1 Top ten sample preparation methods used in flow cytometry, indicated by individuals who participated in FC 2012
Table 17.1 Sample preparation methods used in flow cytometry, indicated by individuals who participated in FC 2012

Figure 18.1 Top ten offline software used in flow cytometry, indicated by individuals who participated in FC 2012
Table 18.1 Offline software used in flow cytometry, indicated by individuals who participated in FC 2012

Figure 19.1 Top ten technical challenges in flow cytometry, indicated by individuals who participated in FC 2012
Table 19.1 Technical challenges used in flow cytometry, indicated by individuals who participated in FC 2012
Figure 19.2 Top ten sample types associated with technical challenges in flow cytometry, indicated by individuals who participated in FC 2012
Table 19.2 Sample types associated with challenges in flow cytometry, indicated by individuals who participated in FC 2012
Figure 19.3 Top ten flow cytometers associated with technical challenges in flow cytometry, indicated by individuals who participated in FC 2012
Table 19.3 Flow cytometers associated with challenges in flow cytometry, indicated by individuals who participated in FC 2012

Figure 20.1 Top five areas of required innovation in flow cytometry, indicated by individuals who participated in FC 2012
Table 20.1 Areas of required innovation in flow cytometry, indicated by individuals who participated in FC 2012

Figure 21.1 Top ten disease biomarkers studied using flow cytometry, indicated by individuals who participated in FC 2012
Table 21.1 Disease biomarkers studied using flow cytometry, indicated by individuals who participated in FC 2012
Figure 21.2 Top five disease biomarker clinical utilities in flow cytometry, indicated by individuals who participated in FC 2012
Table 21.2 Disease biomarkers clinical utilities in flow cytometry, indicated by individuals who participated in FC 2012

Figure 22.1 Annual budgets for the use of flow cytometry, indicated by individuals who participated in FC 2012
Figure 22.2 Average costs/per sample using flow cytometry, indicated by individuals who participated in FC 2012
Figure 22.3 Budget breakdown in nine key areas in flow cytometry, indicated by individuals who participated in FC 2012
Figure 22.4 Future budget changes (increases or decreases) relating to the use of flow cytometry, indicated by individuals who participated in FC 2012

Figure 23.1 Top ten consumables used in flow cytometry, indicated by individuals who participated in FC 2012
Table 23.2 Consumables used in flow cytometry, indicated by individuals who participated in FC 2012

Figure 24.1 Top ten quality control systems or procedures followed by flow cytometry users, indicated by individuals who participated in FC 2012
Table 24.1 Quality control systems or procedures followed by flow cytometry users, indicated by individuals who participated in FC 2012

Visitor Comments

All Comments

Change Currency

GBP

EURO

USD

Last Viewed

Flow Cytometry 2012: A Focus on Sales Growth

Healthcare and Medical Company Profiles

Find latest Healthcare and Medical Company Profiles with up to date financial, strategic, operational, SWOT analysis and product information for the leading healthcare and medical companies.

Competitor Tracking

Do you need to track your competitors and customers on a continuous basis? We have the expertise to provide you with a cost-effective, fully customised competitor tracking portal, which collates data on your competitors on a continuous basis. Contact us for a free consultation and demonstration.

Become an Affiliate

Do you manage an industry specific website or blog? Are you looking to monetise your web traffic further? Are you a B2B website?

Why not offer your visitors industry specific strategic market reports and company profiles? Our Affiliate Program enables you to provide quality content on your website and to earn money from passing on visitors to our website.

Custom Research

Cannot find what you need? We can tailor a report for you. Complete the Custom Research Form and we will provide a quote.

Healthcare and Medical	Type	Keywords Phrase All Words Any Word
Microsoft Windows users can hold the CTRL Key to select more than one sector or country at a time. Apple users can hold the CMD Key to do the same.	Country	Industry Sector
Publisher	Order By Relevance Date	Published In

All
Afghanistan
Africa
Albania
Algeria
American Samoa
Andorra
Angola
Anguilla
Antigua and Barbuda
Argentina
Armenia
Aruba
Asia
Australia
Austria
Azerbaijan
Bahamas
Bahrain
Bangladesh
Barbados
Belarus
Belgium
Belize
Benin
Bermuda
Bhutan
Bolivia
Bosnia-Herzegovina
Botswana
Bouvet Island
Brazil
British Virgin Islands
Brunei
Bulgaria
Burkina Faso
Burundi
Cambodia
Cameroon
Canada
Cape Verde
Caribbean
Cayman Islands
Central African Republic
Central America
Central Europe
Chad
Chile
China
Christmas Island
Cocos (Keeling) Islands
Colombia
Comoros
Conch Republic
Cook Islands
Costa Rica
Croatia
Cuba
Cyprus
Czech Republic
Democratic Republic of the Congo
Denmark
Djibouti
Dominica
Dominican Republic
Eastern Europe
Ecuador
Egypt
El Salvador
Equatorial Guinea
Eritrea
Estonia
Ethiopia
Europe
Falkland Islands
Faroe Islands
Fiji
Finland
France
French Guiana
French Southern Territories
Gabon
Gambia
Georgia
Germany
Ghana
Gibraltar
Global
Greece
Greenland
Grenada
Guadeloupe (French)
Guam (USA)
Guatemala
Guernsey
Guinea
Guinea Bissau
Guyana
Haiti
Heard Island and McDonald Islans
Holy See
Honduras
Hong Kong
Hungary
Iceland
India
Indonesia
Iran
Iraq
Ireland
Israel
Italy
Ivory Coast
Ivory Coast (Cote D`Ivoire)
Jamaica
Japan
Jersey
Jordan
Kazakhstan
Kenya
Kiribati
Kurdistan
Kuwait
Kyrgyzstan
Laos
Latvia
Lebanon
Lesotho
Liberia
Libya
Liechtenstein
Lithuania
Luxembourg
Macau
Macedonia
Madagascar
Malawi
Malaysia
Maldives
Mali
Malta
Marshall Islands
Martinique (French)
Mauritania
Mauritius
Mayotte
Mexico
Micronesia
Middle East
Moldova
Monaco
Mongolia
Montenegro
Montserrat
Morocco
Mozambique
Myanmar
Namibia
Nauru
Nepal
Netherlands
Netherlands Antilles
New Caledonia (French)
New Zealand
Nicaragua
Niger
Nigeria
Niue
Norfolk Island
North America
North Korea
Northern Mariana Islands
Norway
Oman
Pakistan
Palau
Palestinian Territory
Panama
Papua New Guinea
Paraguay
Peru
Philippines
Pitcairn Island
Poland
Polynesia (French)
Portugal
Puerto Rico
Qatar
Republic of the Congo
Reunion
Romania
Russia
Rwanda
Saint Barthelemy
Saint Helena
Saint Kitts and Nevis
Saint Lucia
Saint Martin
Saint Pierre and Miquelon
Saint Vincent and Grenadines
Samoa
San Marino
Sao Tome and Principe
Saudi Arabia
Scandinavia
Schengen countries
Senegal
Serbia
Seychelles
Sierra Leone
Singapore
Slovakia
Slovenia
Solomon Islands
Somalia
South Africa
South America
South Georgia and the South Sandwich Islands
South Korea
South Sudan
Spain
Sri Lanka
Sudan
Suriname
Svalbard and Jan Mayen Islands
Swaziland
Sweden
Switzerland
Syria
Taiwan
Tajikistan
Tanzania
Thailand
Timor-Leste (East Timor)
Togo
Tokelau
Tonga
Trinidad and Tobago
Tunisia
Turkey
Turkmenistan
Turks and Caicos Islands
Tuvalu
Uganda
Ukraine
United Arab Emirates
United Kingdom
United States
United States Minor Outlying Islands
Uruguay
Uzbekistan
Vanuatu
Venezuela
Vietnam
Virgin Islands
Wallis and Futuna Islands
Western Sahara
Yemen
Zambia
Zimbabwe

All
Aerospace
Agriculture, Farming & Raw Materials
Automotive and Parts
Business Services
Chemicals
Construction
Consumer Goods
Defence
Energy and Utilities
Environmental
Finance and Banking
Food and Drink
Healthcare and Medical
Industrial
Information Technology
Leisure
Logistics
Media
Paper and Packaging
Publishing and Printing
Real Estate
Retail
Security
Telecommunications
Textiles and Clothing
Transportation
Travel

Flow Cytometry 2012: A Focus on Sales Growth

Select License Type

Flow cytometry market to hit value of $4 billion by 2015

Report Scope

Market Areas

Speak to an Advisor

Select License Type

Table of Contents

1 Introduction

2 Study Participants

3 Purpose of Flow Cytometry

4 Main Activities

5 Flow Cytometric Tests

6 Therapeutic Area

7 Main Diseases

8 Samples

9 General Applications

10 Clinical Applications

11 Main Applications

12 New Applications

13 Emerging Applications

14 Suppliers

15 Main Flow Cytometer, Strengths and Weaknesses

16 Reagents and Assays

17 Sample Preparation

18 Software

19 Challenges

20 Innovation

21 Disease Biomarkers

22 Flow Cytometry Expenditure and Budgets

23 Consumables

24 Quality Control

List of Figures and Tables

Visitor Comments

Change Currency

Last Viewed

Healthcare and Medical Company Profiles

Competitor Tracking

Become an Affiliate

Custom Research

News

Market Insights

Companies And Markets

Customer Support

Corporate Accounts

Contact Details

Contrast settings

Text size settings